膣薬物送達のイノベーター

Callavid^® is at clinical stage for fertility and threatened miscarriage, with future applications in menopause, cancer, infectious diseases, and delivery of live biotherapeutics.

— As featured in —

患者アウトカムを改善するには、新しく革新的な女性専用の薬物送達システムが必要

詳細を確認する about the current state of vaginal drug delivery

Calla Lily Clinical Care' semi-automated machinery

Calla Lily Clinical Careは、注目に値するいくつかの利点を備えた新しい膣薬物送達デバイスの特許を取得

詳細を確認する about the Callavid® technology and how it can improve drug delivery and patient experiences

“Callavid will be unbelievably popular with miscarriage patients as pessary leakage is the most frequent complaint, causing significant anxiety. The benefits of reducing psychological trauma, anxiety and depression are badly needed.”

Professor Siobhan Quenby

Director Biomedical Research Unit in Reproductive Health,
Professor of Obstetrics University of Warwick,
Deputy Director Tommy’s National Centre for Miscarriage Research,
Calla Lily Clinical Care Medical Advisor

The vagina’s huge medical potential has gone untapped, but not for much longer

“Calla Lily has developed a new leak-free vaginal drug delivery platform. It's simple to use (essential when patients have to administer medications themselves) and also helps to alleviate dosage anxiety and other stresses”

“NICEの新しい流産管理のガイダンスのおかげで、流産発生率の減少に役立つ処方薬として初の推奨薬、微粉化膣プロゲステロンができました。Calla Lily Clinical Careの新しいデバイスは、漏れや経膣的に送達されるプロゲステロン関連のこれまでの不便さの問題に対処しています。”

Stuart Lavery博士

（UCLHの女性健康部門臨床部長／Calla Lily Clinical Care医療顧問）

“This novel platform is of great benefit to anyone using a vaginally-delivered medication. By addressing the major issue of leakage, women can be assured the device delivers the correct dose in a convenient, tidy and less invasive fashion. It is truly a transformative device.”

Dr Kelle Moley

Former Deputy Director of Reproductive Health Technologies
at the Bill & Melinda Gates Foundation,
Calla Lily Clinical Care Medical Advisor